RBC Capital has revised its price target for DexCom (DXCM, Financial), lowering it to $100 from the previous $115, while maintaining an Outperform rating on the shares. This adjustment is part of a broader analysis as the firm previews first-quarter results for the medical devices sector.
The research note highlights that the general trends of underlying procedure volume and capital placements have been robust, aligning with expected seasonal patterns. These factors are anticipated to enable companies within the coverage to surpass quarterly expectations.
Additionally, the analyst notes that recent foreign exchange movements have shifted favorably for large-cap medical device firms with significant international operations. However, these factors have not yet been integrated into consensus estimates for the first quarter or for projections through to 2025.
Regarding tariffs, the firm expects that many companies will offer clarifications on the impact. Despite this, it is noted that numerous firms have either a substantial manufacturing presence in the U.S. or relatively lower tariff exposure compared to other large-cap entities.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for DexCom Inc (DXCM, Financial) is $101.20 with a high estimate of $120.00 and a low estimate of $80.00. The average target implies an upside of 50.18% from the current price of $67.39. More detailed estimate data can be found on the DexCom Inc (DXCM) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, DexCom Inc's (DXCM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM, Financial) in one year is $174.24, suggesting a upside of 158.55% from the current price of $67.39. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the DexCom Inc (DXCM) Summary page.
